284 related articles for article (PubMed ID: 17223877)
1. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects.
Schmidt E; Seitz CS; Benoit S; Bröcker EB; Goebeler M
Br J Dermatol; 2007 Feb; 156(2):352-6. PubMed ID: 17223877
[TBL] [Abstract][Full Text] [Related]
2. Rituximab in refractory autoimmune bullous diseases.
Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
[TBL] [Abstract][Full Text] [Related]
3. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris.
Faurschou A; Gniadecki R
Int J Dermatol; 2008 Mar; 47(3):292-4. PubMed ID: 18289336
[TBL] [Abstract][Full Text] [Related]
4. Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris.
Barrera MV; Mendiola MV; Bosch RJ; Herrera E
J Dermatolog Treat; 2007; 18(5):312-4. PubMed ID: 17852643
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients.
Goh MS; McCormack C; Dinh HV; Welsh B; Foley P; Prince HM
Br J Dermatol; 2007 May; 156(5):990-6. PubMed ID: 17355229
[TBL] [Abstract][Full Text] [Related]
6. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins.
Shimanovich I; Nitschke M; Rose C; Grabbe J; Zillikens D
Br J Dermatol; 2008 Feb; 158(2):382-8. PubMed ID: 18070210
[TBL] [Abstract][Full Text] [Related]
7. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).
Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R
Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus.
Arin MJ; Engert A; Krieg T; Hunzelmann N
Br J Dermatol; 2005 Sep; 153(3):620-5. PubMed ID: 16120153
[TBL] [Abstract][Full Text] [Related]
9. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody).
Dupuy A; Viguier M; Bédane C; Cordoliani F; Blaise S; Aucouturier F; Bonnetblanc JM; Morel P; Dubertret L; Bachelez H
Arch Dermatol; 2004 Jan; 140(1):91-6. PubMed ID: 14732665
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of rituximab in a case of refractory bullous pemphigoid].
Reguiaï Z; Tchen T; Perceau G; Bernard P
Ann Dermatol Venereol; 2009 May; 136(5):431-4. PubMed ID: 19442800
[TBL] [Abstract][Full Text] [Related]
11. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature.
Cianchini G; Corona R; Frezzolini A; Ruffelli M; Didona B; Puddu P
Arch Dermatol; 2007 Aug; 143(8):1033-8. PubMed ID: 17709662
[TBL] [Abstract][Full Text] [Related]
12. A single cycle of rituximab for the treatment of severe pemphigus.
Joly P; Mouquet H; Roujeau JC; D'Incan M; Gilbert D; Jacquot S; Gougeon ML; Bedane C; Muller R; Dreno B; Doutre MS; Delaporte E; Pauwels C; Franck N; Caux F; Picard C; Tancrede-Bohin E; Bernard P; Tron F; Hertl M; Musette P
N Engl J Med; 2007 Aug; 357(6):545-52. PubMed ID: 17687130
[TBL] [Abstract][Full Text] [Related]
13. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients.
Kasperkiewicz M; Shimanovich I; Ludwig RJ; Rose C; Zillikens D; Schmidt E
J Am Acad Dermatol; 2011 Sep; 65(3):552-558. PubMed ID: 21641080
[TBL] [Abstract][Full Text] [Related]
14. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.
Ahmed AR; Spigelman Z; Cavacini LA; Posner MR
N Engl J Med; 2006 Oct; 355(17):1772-9. PubMed ID: 17065638
[TBL] [Abstract][Full Text] [Related]
15. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.
El-Hallak M; Binstadt BA; Leichtner AM; Bennett CM; Neufeld EJ; Fuhlbrigge RC; Zurakowski D; Sundel RP
J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113
[TBL] [Abstract][Full Text] [Related]
16. Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid.
Mazzi G; Raineri A; Zanolli FA; Da Ponte C; De Roia D; Santarossa L; Guerra R; Orazi BM
Transfus Apher Sci; 2003 Feb; 28(1):13-8. PubMed ID: 12620264
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in refractory pemphigus vulgaris.
Sorce M; Aricò M; Bongiorno MR
Dermatol Ther; 2008 Jul; 21 Suppl 1():S6-9. PubMed ID: 18727815
[TBL] [Abstract][Full Text] [Related]
18. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
19. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases.
Segura S; Iranzo P; Martínez-de Pablo I; Mascaró JM; Alsina M; Herrero J; Herrero C
J Am Acad Dermatol; 2007 Jun; 56(6):960-7. PubMed ID: 17368865
[TBL] [Abstract][Full Text] [Related]
20. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases.
Daoud YJ; Amin KG
Int Immunopharmacol; 2006 Apr; 6(4):600-6. PubMed ID: 16504922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
